Literature DB >> 22542045

Central nervous system complications of cancer therapy.

Mikael L Rinne1, Eudocia Q Lee, Patrick Y Wen.   

Abstract

As more effective therapies prolong the survival of patients with cancer, therapy-related toxicities, particularly those affecting the central nervous system (CNS) become increasingly important. CNS complications can cause significant morbidity and can limit the dose or duration of otherwise effective treatments. Because effects on the CNS are disabling and often permanent and treatments remain limited, it is important that clinicians recognize the effects of cancer therapy on the CNS. Cytotoxic chemotherapy and radiation are well-known causes of neurotoxicity, but there is increasing recognition that novel therapies are also sources of adverse effects on the CNS. This review highlights the CNS complications that result from radiation, chemotherapy, and novel therapeutics.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542045     DOI: 10.1016/j.suponc.2011.11.002

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  8 in total

1.  The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study.

Authors:  A Zarabla; S Ungania; A Cacciatore; A Maialetti; G Petreri; A Mengarelli; A Spadea; F Marchesi; D Renzi; Svitlana Gumenyuk; L Strigari; Marta Maschio
Journal:  Funct Neurol       Date:  2017 Oct/Dec

2.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.

Authors:  Dominic Pilon; Ajay S Behl; Lorie A Ellis; Marie-Noëlle Robitaille; Patrick Lefebvre; Nancy A Dawson
Journal:  Am Health Drug Benefits       Date:  2017-05

3.  Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin.

Authors:  Mohammad Waseem; Suhel Parvez
Journal:  Protoplasma       Date:  2015-05-29       Impact factor: 3.356

4.  Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report.

Authors:  Hideyuki Arita; Yoshitaka Narita; Makoto Ohno; Yasuji Miyakita; Yoshiko Okita; Takafumi Ide; Soichiro Shibui
Journal:  Childs Nerv Syst       Date:  2012-10-30       Impact factor: 1.475

5.  Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.

Authors:  Marilena Colaianna; Sten Ilmjärv; Hedi Peterson; Ilse Kern; Stephanie Julien; Mathurin Baquié; Giorgia Pallocca; Sieto Bosgra; Agapios Sachinidis; Jan G Hengstler; Marcel Leist; Karl-Heinz Krause
Journal:  Arch Toxicol       Date:  2016-03-25       Impact factor: 5.153

6.  Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study.

Authors:  Hongqing Zhuang; Hongxia Zhuang; Siyu Shi; Yuxia Wang
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

7.  A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis.

Authors:  Hongqing Zhuang; Xiangkun Yuan; Yi Zheng; Xubin Li; Joe Y Chang; Junjie Wang; Xiaoguang Wang; Zhiyong Yuan; Ping Wang
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379

8.  Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.

Authors:  Lotte Van Der Weijst; Veerle Surmont; Wim Schrauwen; Yolande Lievens
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.